**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2016-2017/283

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | DROX 250 ORAL SUSPENSION | | **REF. NO: NDQD201602763** |
| **DATE RECEIVED:** 18.02.2016 | **LABEL CLAIM:** | Each 5 mL of reconstituted suspension contains: Cefadroxil Monohydrate BP equivalent to Cefadroxil 250 mg. | |
| **BATCH NO.:** ODXDA5016A | **PRESENTATION:** | Off-white coloured powder for reconstitution into suspension for oral administration, contained in a 100 mL translucent plastic bottle packed along with a 10 mL graduated plastic measuring cap in a printed box. | |
| **MFG. DATE:** Sep. 2015 | **MANUFACTURER:** | AUROBINDO Pharma Ltd. | |
| **EXP. DATE:**  Aug. 2018 | **ADDRESS:** | Unit VI, Survey No. 329/39 & 329/47, Chitkul (V), Patancheru Mandal, Medak District, (A.P.), INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | Tanzania Food & Drug Authority (TFDA), Mandela Road, Mabibo-External, P.O BOX 77150, Dar es Saleam, TANZANIA | |
| 021/D/I/1516 | **TEST(S) REQUESTED:** | Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPENDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Assay** | HPLC | USP 38 NF 33 Page 2644 | 90.0 - 120.0% | Day 1 104.5% (RSD=1.9%; n=15) | **COMPLIES** |
| **Assay** |  |  |  | Day 7 100.7% (RSD=2.6%; n=18) |  |

**CONCLUSION:** The sample complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| **ANALYST:** | DR. J. CHEPCHUMBA | .......................................................... | DATE: 04-18-2016 |
| **ANALYST:** | DR. N. MWAURA | .......................................................... | DATE: 06-03-2016 |
| **ANALYST:** | ERNEST MBAE | .......................................................... | DATE: 07-04-2016 |
| **DIRECTOR:** | HEZEKIAH CHEPKWONY | .......................................................... | DATE: 11-23-2016 |